Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy on the Risk of Arterial Thromboembolic Events A Meta-Analysis 英文参考文献.docVIP

下载本文档

4
0
约3.23万字
约 8页
2017-05-11 发布于上海
举报
版权申诉

Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy on the Risk of Arterial Thromboembolic Events A Meta-Analysis 英文参考文献.doc

1、本文档共8页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy on the Risk of Arterial Thromboembolic Events A Meta-Analysis 英文参考文献

EffectofIntravitrealAnti-VascularEndothelialGrowth FactorTherapyontheRiskofArterialThromboembolic Events:AMeta-Analysis Jin-WeiCheng1.,Shi-WeiCheng2.,Guo-CaiLu3*,Rui-LiWei1* 1Department of Ophthalmology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, 2School of Life Sciences, Ludong University, Yantai,China,3CenterforNewDrugEvaluation,InstituteofBasicMedicalScience,SecondMilitaryMedicalUniversity,Shanghai,China Abstract Background: Intravitreal anti-vascular endothelial growth factor (VEGF) monoclonal antibodies are used in ocular neovasculardiseases.Aconsensushasemergedthatintravenousanti-VEGFcanincreasetheriskofarterialthromboembolic events. However, the role of intravitreal anti-VEGF in arterial thromboembolism is controversial. Therefore, we did a systematic review and meta-analysis to investigate the effects of intravitreal anti-VEGF on the risk of arterial thromboembolicevents. Methods:Electronicdatabasesweresearchedtoidentifyrelevantrandomizedclinicaltrialscomparingintravitrealanti-VEGF withcontrols.Criteriaforinclusioninourmeta-analysisincludedastudydurationofnolessthan12months,theuseof a randomized control group not receiving any intravitreal active agent, and the availability of outcome data for arterial thromboembolicevents,myocardialinfarction,cerebrovascularaccidents,andvasculardeath.Theriskratiosand95%CIs werecalculatedusingafixed-effectsorrandom-effectsmodel,dependingontheheterogeneityoftheincludedstudies. Results:Atotalof4942patientswithavarietyofocularneovasculardiseasesfrom13randomizedcontrolledtrialswere identifiedandincludedforanalysis.Therewasnosignificantdifferencebetweenintravitrealanti-VEGFandcontrolintherisk ofallevents,withriskratiosof0.87(95%CI,0.64to1.19)forarterialthromboembolicevents,0.96(95%CI,0.55–1.68)for cerebrovascularaccidents,0.69(95%CI0.40–1.21)formyocardialinfarctions,and0.68(95%CI,0.37–1.27)forvasculardeath. Conclusions: The strength evidence suggests that the intravitreal use of anti-VEG